Manipal Health IPO: GMP, Pricing Insights, Allotment Details, and 2026 Profit Projections Revealed!
Manipal Health Enterprises, one of the largest private healthcare providers in India, is preparing for an IPO that promises to bolster its already expansive network. With 38 hospitals currently in operation and plans to expand to 49 hospitals and over 12,600 beds by the end of 2025, the company has crafted a robust growth strategy focusing on both organic capacity expansion and strategic acquisitions. Financial performance for FY2025 showcases a pro forma revenue of INR 9,263.6 crore and an EBITDA margin of 26.7%, indicating operational efficiency. The IPO will consist of a fresh issue of INR 8,000 crore and an Offer for Sale of approximately 4.32 crore shares, with listing expected on both the NSE and BSE, though specific dates are yet to be announced.
The grey market sentiment surrounding the Manipal Health IPO has not been explicitly referenced, but the company’s strong financials and growth potential generally evoke a positive outlook among investors. Given the increasing demand for quality healthcare services in India, driven by a rising middle class and greater health awareness, a favorable reception in the grey market can be expected. The nuances of the offer must be monitored as the market approaches the IPO date, particularly in terms of pricing and demand from institutional and retail investors.
For Indian investors, the Manipal Health IPO presents a compelling opportunity to participate in the healthcare sector, which is poised for significant growth. With its established reputation and expansion plans, investors have a chance to tap into a sector that plays a crucial role in the nation’s well-being. The anticipated use of proceeds from the IPO for debt repayment and acquisitions adds further confidence in the company’s financial management and growth trajectory. Overall, this IPO could represent not just a financial investment, but a commitment to supporting India’s healthcare landscape during a transformative period.
Source: The Economic Times
(Expert Note: This report was prepared by the Wealthova IPO team.)